<DOC>
	<DOCNO>NCT02401555</DOCNO>
	<brief_summary>The purpose study evaluate performance Bio-Rad Geenius HIV 1/2 Supplemental Assay , single-use immunochromatographic assay confirmation differentiation individual antibody Human Immunodeficiency Virus Types 1 2 ( HIV-1 HIV-2 ) fingerstick whole blood , venous whole blood , serum , plasma sample ( EDTA , heparin , sodium citrate ) .</brief_summary>
	<brief_title>Performance Evaluation Bio-Rad Geenius HIV1/2 Supplemental Assay</brief_title>
	<detailed_description>Prospectively collect matched sample type , include fingerstick ( capillary blood ) , serum , plasma , whole venous blood obtain subject three clinical trial site within United States . Informed consent use enroll subject low risk HIV ( N=120 subject ) subject pre-diagnosed HIV positive ( N=299 subject ) . The fingerstick sample test Geenius HIV 1/2 Supplemental Assay collection site , remain match sample type , ( serum , plasma , whole venous blood ) send clinical lab test Geenius HIV 1/2 Supplemental Assay . Results Geenius HIV 1/2 Supplemental Assay 4 match sample compare serum result Bio-Rad GS HIV 1/HIV 2 PLUS O EIA , Bio-Rad HIV-1 Western blot , Bio-Rad Multispot HIV 1/HIV-2 Rapid Test ( reference method ) . Retrospective specimen repository specimen purchase commercial vendor also include study . In addition Geenius HIV 1/2 Supplemental Assay , GS HIV 1/HIV 2 PLUS O EIA , Bio-Rad HIV-1 Western blot , Bio-Rad Multispot HIV 1/HIV-2 Rapid Test utilize reference method . Historical data , available , also use . All sample identify unique study number include following populations/panels : 1 . HIV-1/HIV-2 False Reactive Samples ( N=100 ) 2 . Unrelated Medical Conditions ( N=40 ) . 3 . Normal Pediatric Patients ( N=10 ) 4 . HIV-1 Positive Pediatric Patients ( N=40 ) 5 . HIV-1 Non B Group M Subtypes ( N=136 ) 6 . HIV-1 Group O Antibody Positive ( N=15 ) 7 . Known HIV-2 Positive Population ( N=200 ) 8 . HIV Performance Panels 1 . Anti-HIV-1/2 Combo Performance Panel : PRZ208 ( N=15 ) 2 . HIV-1 Low Titer Panel : PRB109 ( N=20 ) 3 . HIV-1 Incidence / Prevalence Panel : PRB601 ( N=15 ) 4 . HIV-1 Seroconversion Panels ( 26 Panels , N=230 ) 9 . CEPHIA Evaluation Panel ( N=2500 )</detailed_description>
	<criteria>Inclusion Criteria HIV1 positives AIDS positive population : Should able provide inform consent . Must great equal 18 year age . Agree provide finger stick sample . Agree provide upto 20 mL blood venipuncture . Must sufficient medical history provide data require case report form . Exclusion Criteria HIV1 positives AIDS positive population : Unable provide inform consent Subjects receive experimental vaccine HIV . Individuals except AIDS patient currently ARV therapy duration start therapy 6 month . Inclusion Criteria Low Risk population : Able provide Informed consent Must great equal 18 year age . Subject report high risk behavior HIV infection . Of unknown HIV status . Exclusion criteria Low Risk Population : Unable provide inform consent . Individuals one high risk behavior HIV infection within previous 6 month . Self report history HIV infection Prior receipt HIV infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>